Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Τρίτη 11 Σεπτεμβρίου 2018

Effect of remifentanil on postoperative nausea and vomiting: a randomized pilot study

Abstract

Opioid-related postoperative nausea and vomiting should not occur following remifentanil administration because of its relatively short time to elimination. However, studies have indicated that the incidence of postoperative nausea and vomiting associated with remifentanil is similar to that with other opioids. Hence, we aimed to determine whether intraoperative remifentanil itself is associated with postoperative nausea and vomiting when postoperative pain is managed without opioid use. In this prospective pilot study, 150 patients who underwent unilateral upper limb surgery under general anesthesia with brachial plexus block were included. Patients in the remifentanil and control groups received 0.5 µg/kg/min remifentanil and saline, respectively. Postoperative pain was managed using a brachial plexus block, non-steroidal anti-inflammatory drugs, and acetaminophen. The presence of postoperative nausea and vomiting within the first 24 h after anesthesia was assessed by an evaluator blinded to patient allocation. Eight patients were excluded from the final analysis, resulting in 72 and 70 patients in the remifentanil and control groups, respectively. Postoperative nausea and vomiting within 24 h after surgery occurred in 11 and 9 patients in the remifentanil and control groups, respectively. These data suggest that remifentanil use only minimally affects the incidence of postoperative nausea and vomiting under sevoflurane anesthesia.

UMIN Clinical Trials Registry identification number: UMIN000016110.



https://ift.tt/2oWFH9A

Dominant men are faster in decision-making situations and exhibit a distinct neural signal for promptness

Abstract
Social dominance, the main organizing principle of social hierarchies, facilitates priority access to resources by dominant individuals. Throughout taxa, individuals are more likely to become dominant if they act first in social situations and acting fast may provide evolutionary advantage; yet whether fast decision-making is a behavioral predisposition of dominant persons outside of social contexts is not known. Following characterization of participants for social dominance motivation, we found that, indeed, men high in social dominance respond faster–without loss of accuracy–than those low in dominance across a variety of decision-making tasks. Both groups did not differ in a simple reaction task. Then, we selected a decision-making task and applied high-density electroencephalography (EEG) to assess temporal dynamics of brain activation through event related potentials. We found that promptness to respond in the choice task in dominant individuals is related to a strikingly amplified brain signal at approximately 240 ms post-stimulus presentation. Source imaging analyses identified higher activity in the left insula and in the cingulate, right inferior temporal and right angular gyri in high than in low dominance participants. Our findings suggest that promptness to respond in choice situations, regardless of social context, is a biomarker for social disposition.

https://ift.tt/2CJn6rc

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Conditions:   Advanced or Metastatic Solid Tumors;   Head and Neck Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer
Intervention:   Drug: NC318
Sponsor:   NextCure, Inc.
Not yet recruiting

https://ift.tt/2x91xKW

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Condition:   Recurrent Nasopharyngeal Carcinoma
Intervention:   Drug: Nimotuzumab
Sponsors:   Fujian Cancer Hospital;   Sun Yat-sen University;   Jiangxi Provincial Cancer Hospital;   Zhejiang Cancer Hospital;   Fujian Medical University Union Hospital
Recruiting

https://ift.tt/2x3xN1J

A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254

Condition:   Advanced Solid Tumor
Intervention:   Drug: BAY1905254
Sponsor:   Bayer
Not yet recruiting

https://ift.tt/2x1G9rJ

Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

Condition:   Skin Neoplasm
Interventions:   Drug: Pembrolizumab;   Drug: Cetuximab
Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   Merck Sharp & Dohme Corp.
Not yet recruiting

https://ift.tt/2x91KxI

Pathophysiological Mechanism Behind Prolonged Whiplash Associated Disorders

Condition:   Whiplash Injuries
Intervention:   Other: Exercises
Sponsor:   Linkoeping University
Not yet recruiting

https://ift.tt/2x0J6sA

Αρχειοθήκη ιστολογίου